Table 3 Logistics regression analysis of atrial fibrillation among adult rheumatic heart disease patients at TGSH and FHCSH hospitals in Bahir Dar town, Northwest Ethiopia, 2024(n = 402)

Age

 < 31

40 /32%

85 /68%

1

 < 0.001

1

0.023

31–40

32 /45.7%

38 /54.3%

1.78 (0.98–3.26)

0.058

2.04(0.58–7.22)

0.266

41–50

62 /62.6%

37 /37.4%

3.56 (2.04–6.19)

 < 0.001

2.21(0.71–6.92)

0.171

 > 50

72 /66.7%

36 /33.3%

4.25 (2.45–7.35)

 < 0.001

7.20(2.03–25.46)

0.002 \(*\)

Alcohol drinking

Yes

54 /69.2%

24 /30.8%

2.54 (1.50–4.31)

0.001

1.97(0.41–9.38)

0.390

No

152 /46.9%

172 /53.1%

1

1

Cigarate smoking

Yes

47 /67.1%

23 /32.9%

2.22 (1.29–3.82)

0.004

0.46(0.09–2.16)

0.326

No

159 /47.9%

173 /52.1%

1

1

No MS

No

14 /12.8%

95 /87.2%

1

 < 0.001

1

0.702

Mild

5 /9.8%

46 /90.2%

0.73 (0.25–2.17)

0.581

1.43(0.27–7.54)

0.667

Moderate

62 /67.4%

30 /32.6%

14.02 (6.89- 28.53)

 < 0.001

2.99(0.48–18.33)

0.236

Severe

125 /83.3%

25 /16.7%

32.92 (16.73–68.77)

 < 0.001

2.97(0.35–24.99)

0.315

MR status

No

68 /74.7%

23 /25.3%

1

 < 0.001

1

0.070

Mild

64 /61%

41 /39%

0.52 (0.28- 0.97)

0.042

2.30(0.64–8.21)

0.196

Moderate

49 /32.2%

103 /67.8%

0.16 (0.09–0.28)

 < 0.001

0.78(0.32–2.54)

0.681

Severe

25 /46.3%

29 /53.7%

0.29(0.14–0.59)

0.001

3.89(0.85–17.74)

0.079

TR status

No

20 /15.3%

111/84.7%

1

 < 0.001

1

0.011

Mild

16 /28.8%

40 /71.2%

2.24 (1.07–4.69)

0.032

0.54(0.15–1.91)

0.345

Moderate

72 /68.8%

32 /31.2%

12.24 (6.55–22.87)

 < 0.001

2.83(0.93–8.65)

0.067

Severe

101/91.3%

10/8.7%

56.05 (25.19–133.37)

 < 0.001

4.50(1.18–17.20)

0.028 \(*\)

AR status

No

135 /64.9%

73 /35.1%

1

 < 0.001

1

0.681

Mild

36 /61.7%

58 /38.3%

0.33 (0.20–0.55)

 < 0.001

1.99(0.63–6.20)

0.235

Moderate

24 /30.8%

54 /69.2%

0.24 (0.13–0.42)

 < 0.001

1.91(0.36–3.91)

0.770

Severe

11 /50%

11 /50%

0.54 (0.22–1.30)

0.172

1.01(0.21–4.72)

0.988

NYHA functional class

No

39 /29.8%

92 /70.2%

1

 < 0.001

1

0.804

Class I

5 /16.7%

25 /83.3%

0.47 (0.16–1.32)

0.153

0.81(0.11–5.77)

0.838

Class II

37 /62.7%

22 /37.2%

3.96 (2.07–7.57)

 < 0.001

1.29(0.32–5.22)

0.715

Class III

68 /71.6%

27 /28.4%

5.94 (3.31–10.63)

 < 0.001

2.03(0.60–6.85)

0.251

Class IV

57 /65.5%

30 /34.5%

4.48 (2.51–8.00)

 < 0.001

1.49(0.42–5.20)

0.529

Ischemic heart disease

Yes

40 / 67.8%

19 /32.2%

2.24 (1.25–4.03)

0.007

1.93(0.54–6.82)

0.307

No

166 /48.4%

177 / 51.6%

1

1

Dyslipidemia

Yes

29 /69%

13 / 31%

2.30 (1.16–4.58)

0.017

0.83(0.26–2.66)

0.759

No

177 /49.2%

183 /50.8%

1

1

Benzanthin penicillin

Yes

159 / 46.4

184 /53.6%

0.22 (0.11–0.43)

 < 0.001

0.63(0.18–2.17)

0.468

No

47 / 79.7%

12 /20.3%

1

1

LVEF in %

Median 52 (IQR 43–60)

0.91(0.89–0.93)

 < 0.001

0.94(0.89–0.99)

0.021 \(*\)

MVA in mm

Median 1. 6 (IQR 0.9–3.62)

0.29 (0.23–0.37)

 < 0.001

0.56(0.28–1.12)

0.103 \(*\)

Left atrium size

Median 49 (IQR 39.75–56)

1.35 (1.28–1.42)

 < 0.001

1.23(1.14–1.33)

 < 0.001 \(**\)

ESR

Median 8 (IQ 5.75–14)

1.05 (1.01–1.07)

0.005

1.03(0.96–1.10)

0.343